Loading patent…
AssigneeSarepta Therapeutics, Inc.
InventorsDan V. Mourich, Patrick L. Iversen, Dwight D. Weller
Estimating the term…
A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
-16. (canceled)
A cytotoxic T-lymphocyte antigen-4 (CTLA-4) antisense oligonucleotide analog compound, comprising a targeting sequence of at least 12 contiguous bases that correspond to a sequence located within the sequence spanning from the 5′-end of SEQ ID NO:4 to the 3′-end of SEQ ID NO:6, wherein the oligonucleotide compound contains from 12 to 40 morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′-exocyclic carbon of an adjacent subunit, and is capable of forming a heteroduplex structure with a pre-processed CTLA-4 mRNA having a Tm of dissociation of at least 45° C.
Dependencies are inferred from the claim text.